{"id":"https://openalex.org/W7225422209","doi":"https://doi.org/10.1186/s40360-026-01276-z","title":"Postmarketing adverse event reporting patterns of methoxy polyethylene glycol-epoetin beta: a two-stage disproportionality analysis of FAERS and JADER with active ESA comparators","display_name":"Postmarketing adverse event reporting patterns of methoxy polyethylene glycol-epoetin beta: a two-stage disproportionality analysis of FAERS and JADER with active ESA comparators","publication_year":2026,"publication_date":"2026-11-06","ids":{"openalex":"https://openalex.org/W7225422209","doi":"https://doi.org/10.1186/s40360-026-01276-z"},"language":"en","primary_location":{"id":"doi:10.1186/s40360-026-01276-z","doi":"https://doi.org/10.1186/s40360-026-01276-z","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s40360-026-01276-z","pdf_url":null,"source":{"id":"https://openalex.org/S29101735","display_name":"BMC Pharmacology and Toxicology","issn_l":"2050-6511","issn":["2050-6511"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Pharmacology and Toxicology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1186/s40360-026-01276-z","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5127847257","display_name":"Jiawei Xu","orcid":"https://orcid.org/0009-0007-5173-7984","observed_orcids":["https://orcid.org/0009-0007-5173-7984"]},"institutions":[{"id":"https://openalex.org/I4210113281","display_name":"Lishui Central Hospital","ror":"https://ror.org/023e72x78","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210113281"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Jiawei Xu","raw_affiliation_strings":["Department of Pharmacy, Lishui Central Hospital, No. 289 Kuocang Road, Lishui, Zhejiang, 323000, China"],"raw_orcid":"https://orcid.org/0009-0007-5173-7984","affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Lishui Central Hospital, No. 289 Kuocang Road, Lishui, Zhejiang, 323000, China","institution_ids":["https://openalex.org/I4210113281"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5161103914","display_name":"Wenwen You","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210113281","display_name":"Lishui Central Hospital","ror":"https://ror.org/023e72x78","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210113281"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Wenwen You","raw_affiliation_strings":["Clinical Trial Office, Lishui Central Hospital, Lishui, Zhejiang, 323000, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Trial Office, Lishui Central Hospital, Lishui, Zhejiang, 323000, China","institution_ids":["https://openalex.org/I4210113281"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5127847257"],"corresponding_institution_ids":["https://openalex.org/I4210113281"],"apc_list":{"value":3090,"currency":"USD","value_usd":3090},"apc_paid":{"value":3090,"currency":"USD","value_usd":3090},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11534","display_name":"Erythropoietin and Anemia Treatment","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/methoxy-polyethylene-glycol-epoetin-beta","display_name":"methoxy polyethylene glycol-epoetin beta","score":0.9959999918937683},{"id":"https://openalex.org/keywords/erythropoiesis-stimulating-agents","display_name":"erythropoiesis-stimulating agents","score":0.9789999723434448},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.6940000057220459},{"id":"https://openalex.org/keywords/disproportionality-analysis","display_name":"disproportionality analysis","score":0.7329999804496765},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.7089999914169312},{"id":"https://openalex.org/keywords/hypersensitivity","display_name":"hypersensitivity","score":0.828000009059906},{"id":"https://openalex.org/keywords/anaphylaxis","display_name":"anaphylaxis","score":0.8069999814033508},{"id":"https://openalex.org/keywords/bone-marrow-failure","display_name":"bone marrow failure","score":0.9200000166893005},{"id":"https://openalex.org/keywords/ventricular-fibrillation","display_name":"ventricular fibrillation","score":0.9769999980926514},{"id":"https://openalex.org/keywords/pure-red-cell-aplasia","display_name":"pure red cell aplasia","score":0.8870000243186951},{"id":"https://openalex.org/keywords/anemia-of-chronic-kidney-disease","display_name":"anemia of chronic kidney disease","score":0.8939999938011169},{"id":"https://openalex.org/keywords/comparator-selection","display_name":"comparator selection","score":0.5360000133514404},{"id":"https://openalex.org/keywords/signaling-specificity","display_name":"signaling specificity","score":0.5260000228881836},{"id":"https://openalex.org/keywords/time-to-onset","display_name":"time to onset","score":0.6029999852180481},{"id":"https://openalex.org/keywords/fda-adverse-event-reporting-system","display_name":"FDA Adverse Event Reporting System","score":0.7350000143051147},{"id":"https://openalex.org/keywords/jader","display_name":"JADER","score":0.921999990940094}],"concepts":[{"id":"https://openalex.org/C2777105317","wikidata":"https://www.wikidata.org/wiki/Q4686710","display_name":"Adverse Event Reporting System","level":3,"score":0.8952999711036682},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7559999823570251},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6736000180244446},{"id":"https://openalex.org/C197636746","wikidata":"https://www.wikidata.org/wiki/Q7234359","display_name":"Postmarketing surveillance","level":3,"score":0.5953999757766724},{"id":"https://openalex.org/C199475168","wikidata":"https://www.wikidata.org/wiki/Q1539689","display_name":"MedDRA","level":4,"score":0.5148000121116638},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4345000088214874},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.429500013589859},{"id":"https://openalex.org/C2779662365","wikidata":"https://www.wikidata.org/wiki/Q5416694","display_name":"Event (particle physics)","level":2,"score":0.39820000529289246},{"id":"https://openalex.org/C195910791","wikidata":"https://www.wikidata.org/wiki/Q1324077","display_name":"Medical record","level":2,"score":0.3456000089645386},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.34470000863075256},{"id":"https://openalex.org/C3018260909","wikidata":"https://www.wikidata.org/wiki/Q1322871","display_name":"Exploratory analysis","level":2,"score":0.32359999418258667},{"id":"https://openalex.org/C2992886853","wikidata":"https://www.wikidata.org/wiki/Q18381816","display_name":"Post hoc","level":2,"score":0.3188999891281128},{"id":"https://openalex.org/C67761136","wikidata":"https://www.wikidata.org/wiki/Q2105849","display_name":"Post-hoc analysis","level":2,"score":0.30480000376701355},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.30390000343322754},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.30379998683929443},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.29660001397132874},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.28110000491142273},{"id":"https://openalex.org/C38180746","wikidata":"https://www.wikidata.org/wiki/Q1952580","display_name":"Multivariate analysis","level":2,"score":0.27480000257492065},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.2696000039577484},{"id":"https://openalex.org/C2780542314","wikidata":"https://www.wikidata.org/wiki/Q45959","display_name":"Adverse drug reaction","level":3,"score":0.2624000012874603}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1186/s40360-026-01276-z","doi":"https://doi.org/10.1186/s40360-026-01276-z","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s40360-026-01276-z","pdf_url":null,"source":{"id":"https://openalex.org/S29101735","display_name":"BMC Pharmacology and Toxicology","issn_l":"2050-6511","issn":["2050-6511"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Pharmacology and Toxicology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1186/s40360-026-01276-z","doi":"https://doi.org/10.1186/s40360-026-01276-z","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s40360-026-01276-z","pdf_url":null,"source":{"id":"https://openalex.org/S29101735","display_name":"BMC Pharmacology and Toxicology","issn_l":"2050-6511","issn":["2050-6511"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Pharmacology and Toxicology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7147402880","https://openalex.org/W7134825645","https://openalex.org/W4393026432","https://openalex.org/W7169807565","https://openalex.org/W4403400235","https://openalex.org/W4406219184","https://openalex.org/W4414254864","https://openalex.org/W4417449241","https://openalex.org/W4389434913","https://openalex.org/W4404834261"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Methoxy":[2],"polyethylene":[3],"glycol-epoetin":[4],"beta":[5],"is":[6],"a":[7],"long-acting":[8],"erythropoiesis-stimulating":[9],"agent":[10],"(ESA)":[11],"used":[12],"for":[13,61,111,118,132,282],"anemia":[14],"associated":[15],"with":[16,200],"chronic":[17],"kidney":[18],"disease.":[19],"Rare":[20],"immunogenic":[21],"events,":[22],"acute":[23,242],"hypersensitivity,":[24,272],"and":[25,37,41,49,82,121,142,159,170,177,209,229,247,255,270],"reduced-response":[26],"reporting":[27,35,79,84,207,256],"patterns":[28,36],"require":[29],"long-term":[30],"postmarketing":[31],"assessment.":[32],"We":[33],"characterized":[34],"time":[38],"to":[39,99,107,195],"onset":[40],"assessed":[42],"signal":[43,260],"specificity":[44],"using":[45],"active":[46,122,187],"ESA":[47,123,188,268],"comparators":[48],"two":[50,230,248],"spontaneous-reporting":[51],"databases.":[52],"Methods":[53],"FDA":[54],"Adverse":[55,134],"Event":[56,136],"Reporting":[57],"System":[58],"(FAERS)":[59],"screening":[60],"2018Q1\u20132026Q1":[62],"identified":[63,227],"6,609":[64],"reports":[65,199,291],"mentioning":[66],"the":[67],"target":[68],"drug.":[69],"The":[70,262],"primary-suspect":[71,154],"comparison":[72,189],"yielded":[73,103],"145":[74],"preferred":[75],"terms":[76],"(PTs)":[77],"meeting":[78],"odds":[80],"ratio":[81,85],"proportional":[83],"criteria,":[86],"including":[87],"138":[88],"three-algorithm":[89],"consensus":[90,165,185],"signals.":[91],"In":[92],"parallel,":[93],"an":[94],"exploratory":[95],"source-restricted":[96],"rule":[97],"applied":[98],"402":[100],"count-qualified":[101],"PTs":[102,163],"87":[104],"terms,":[105],"harmonized":[106],"86":[108,158,162],"Medical":[109],"Dictionary":[110],"Regulatory":[112],"Activities":[113],"PTs.":[114],"These":[115],"were":[116,128],"fixed":[117],"lifecycle":[119],"FAERS":[120,151],"comparator":[124],"analyses.":[125],"Eight":[126],"events":[127],"prioritized":[129],"post":[130],"hoc":[131],"Japanese":[133],"Drug":[135],"Report":[137],"(JADER)":[138],"corroboration,":[139],"time-to-onset":[140],"analysis,":[141],"structured":[143],"review":[144],"of":[145,157,161,266],"public":[146,274],"case":[147,275],"fields.":[148],"Results":[149],"Lifecycle":[150],"included":[152],"8,965":[153],"reports;":[155],"38":[156],"29":[160],"met":[164],"versus":[166],"all":[167],"other":[168,172],"drugs":[169],"strict":[171],"ESAs,":[173],"respectively.":[174],"Haemoglobin":[175],"decreased":[176],"pure":[178],"red":[179],"cell":[180],"aplasia":[181],"did":[182,277],"not":[183,278],"meet":[184],"under":[186],"in":[190],"FAERS.":[191],"Anaphylactic":[192],"reaction":[193],"tended":[194],"occur":[196],"early":[197],"among":[198],"evaluable":[201],"dates;":[202],"its":[203],"disproportionality":[204],"varied":[205],"by":[206],"source":[208],"period.":[210],"Among":[211,234],"22":[212],"bone":[213,284],"marrow":[214,285],"failure":[215,286],"reports,":[216,238],"16":[217],"had":[218,225,231,249],"competing":[219],"explanations":[220],"or":[221,244,287,295],"event":[222,245],"overlap,":[223],"four":[224],"no":[226],"alternative,":[228],"insufficient":[232,250],"information.":[233,251],"nine":[235],"ventricular":[236,288],"fibrillation":[237],"seven":[239],"occurred":[240],"within":[241],"alternative":[243],"chains":[246],"Conclusions":[252],"Comparator":[253],"choice":[254],"context":[257],"materially":[258],"changed":[259],"interpretation.":[261],"findings":[263],"support":[264],"surveillance":[265],"known":[267],"immunogenicity":[269],"severe":[271],"but":[273],"fields":[276],"provide":[279],"positive":[280],"evidence":[281],"target-drug-specific":[283],"fibrillation.":[289],"Spontaneous":[290],"cannot":[292],"estimate":[293],"incidence":[294],"establish":[296],"causality.":[297]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-11-07T00:00:00"}